title: Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients.
abstract: Neutropenia is a severe adverse effect that can occur when treating patients with imatinib mesylate for advanced-stage chronic myelogenous leukaemia (CML). Therefore, we evaluated in vitro the combined effect of imatinib and granulocyte colony-stimulating factor (G-CSF) on proliferation and apoptosis of Bcr-Abl-expressing leukaemic cells to infer the safety of G-CSF administration. In KU812 and K562 cell lines, G-CSF neither stimulated their proliferation nor abolished the suppressive effect of imatinib. However, it stimulated the proliferation of blast cells in 2 out of the 5 cases with advanced-stage CML. These in vitro studies appear to provide data for the decision of G-CSF administration in combination with imatinib in the treatment of neutropenic patients with advanced-stage CML.
authors.affiliation: Department of Internal Medicine, Gastroenterology and Hematology Section, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ota
authors.forename: Manabu
authors.initials: M
authors.lastname: Musashi
authors.forename: Keiichi
authors.initials: K
authors.lastname: Kondo
authors.forename: Nobuyasu
authors.initials: N
authors.lastname: Toyoshima
authors.forename: Tomomi
authors.initials: T
authors.lastname: Toubai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Onozawa
authors.forename: Akio
authors.initials: A
authors.lastname: Mori
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hashino
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Matsuno
authors.forename: Masahiro
authors.initials: M
authors.lastname: Imamura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects*; D004336:Drug Antagonism; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D016313:Genes, abl; D016179:Granulocyte Colony-Stimulating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D010879:Piperazines / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D016179:Granulocyte Colony-Stimulating Factor; D000068877:Imatinib Mesylate